Booklet updates: ​Myelodysplastic Syndromes (MDS)

The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.

​Myelodysplastic Syndromes and The MDS Guide: Information for Patients and Caregivers

• In June 2024, the Food and Drug Administration (FDA) approved imetelstat (Rytelo) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).